CH-4051 + folic acid

CH-4051 + folic acid is a **combination drug** studied for the treatment of rheumatoid arthritis. **CH-4051** is a novel antifolate compound, designed as a next-generation derivative with improved efficacy compared to methotrexate, targeting folate-dependent pathways associated with inflammation and immune cell proliferation. It is paired in clinical development with **folic acid**, a synthetic form of vitamin B9 used to prevent folate deficiency and reduce the toxicity associated with antifolate therapies. The combination aims to balance antifolate efficacy with reduced side effects related to folate depletion. Clinical trials have evaluated this combination for efficacy and safety parameters in rheumatoid arthritis, such as improvement in joint stiffness and American College of Rheumatology (ACR20, 50, 70) response rates[2][4].